Flutemetamol F18 Injection – For early onset of Alzheimer PET scan

Flutemetamol F18 Injection – For early onset of Alzheimer PET scan

The First-and-Only Amyloid Imaging Agent with FDA Approval for Color Image Interpretation

Flutemetamol F18 Injection color images provided accurate amyloid detection

In Study 1:
Hign median sentivity and specificity in autopsy standard-of-truth assesment among five independent, blinded image readers.

In Study 2:

  • Flutemetamol F18 Injection color image reads demonstrated high inter-reader agreement for visual image interpretation (kappa score 0.83, 95% CI [0.79-086]).
  • An intra-reader reproducibility analysis involving two readings for each of 29 duplicate patient images showed: One of the five readers ahd complete agreement for all 29 images, two readers had discordant reads for a single image, and two readers had discordant reads for two images.
  • Intra-reader reproducibility for a subgroup of eight images from aMCI patients showed: All five readers had complete agreement for all duplicate images.
*AMCI – Amnestic Mild Cognitive Impairment


  • A negative Flutemetamol F18 Injection scan indicates sparse to no neuritic plaques and is inconsistent with a neuropathological diagnosis of Alzheimer’s disease at the point of image acquisition
  • A positive Flutemetamol F18 Injection scan indicates moderate to frequent amyloid neuritic plaques
  • Flutemetamol F18 Injection is an adjunct to other diagnostic evaluates


  • With persistent or progressive unexplained MCI
  • Who satisty core clinical criteria for possible Alzheimer’s disease because pf unclear clinical presentation, either a typical clinical course or an etiologically mixed presentation
  • With progressive dementia and a typically early age of onset (usually defined as < 65)


In clinical trials of 761 patients dosed, one experienced a serious hypersensitivity reaction.

  • This reaction was accompanied by flushing, dyspnea, and chest pressure
  • The reaction occured within minutes of administration of Flutemetamol F18 Injection, and the patient recovered with treatment
  • The most commonly reported adverse reactions occured at a rate of <2% and were of mild to moderate intensity
  • The recommended dose is 185 MBq (5 mCi) injected intravenously. The adult effective dose is 5.92 mSv